An Initiative to Decrease Laboratory Testing in a NICU.


Journal

Pediatrics
ISSN: 1098-4275
Titre abrégé: Pediatrics
Pays: United States
ID NLM: 0376422

Informations de publication

Date de publication:
07 2021
Historique:
accepted: 07 12 2020
pubmed: 6 6 2021
medline: 19 11 2021
entrez: 5 6 2021
Statut: ppublish

Résumé

Laboratory testing is performed frequently in the NICU. Unnecessary tests can result in increased costs, blood loss, and pain, which can increase the risk of long-term growth and neurodevelopmental impairment. Our aim was to decrease routine screening laboratory testing in all infants admitted to our NICU by 20% over a 24-month period. We designed and implemented a multifaceted quality improvement project using the Institute for Healthcare Improvement's Model for Improvement. Baseline data were reviewed and analyzed to prioritize order of interventions. The primary outcome measure was number of laboratory tests performed per 1000 patient days. Secondary outcome measures included number of blood glucose and serum bilirubin tests per 1000 patient days, blood volume removed per 1000 patient days, and cost. Extreme laboratory values were tracked and reviewed as balancing measures. Statistical process control charts were used to track measures over time. Over a 24-month period, we achieved a 26.8% decrease in laboratory tests performed per 1000 patient days (∽51 000 fewer tests). We observed significant decreases in all secondary measures, including a decrease of almost 8 L of blood drawn and a savings of $258 000. No extreme laboratory values were deemed attributable to the interventions. Improvement was sustained for an additional 7 months. Targeted interventions, including guideline development, dashboard creation and distribution, electronic medical record optimization, and expansion of noninvasive and point-of-care testing resulted in a significant and sustained reduction in laboratory testing without notable adverse effects.

Sections du résumé

BACKGROUND AND OBJECTIVES
Laboratory testing is performed frequently in the NICU. Unnecessary tests can result in increased costs, blood loss, and pain, which can increase the risk of long-term growth and neurodevelopmental impairment. Our aim was to decrease routine screening laboratory testing in all infants admitted to our NICU by 20% over a 24-month period.
METHODS
We designed and implemented a multifaceted quality improvement project using the Institute for Healthcare Improvement's Model for Improvement. Baseline data were reviewed and analyzed to prioritize order of interventions. The primary outcome measure was number of laboratory tests performed per 1000 patient days. Secondary outcome measures included number of blood glucose and serum bilirubin tests per 1000 patient days, blood volume removed per 1000 patient days, and cost. Extreme laboratory values were tracked and reviewed as balancing measures. Statistical process control charts were used to track measures over time.
RESULTS
Over a 24-month period, we achieved a 26.8% decrease in laboratory tests performed per 1000 patient days (∽51 000 fewer tests). We observed significant decreases in all secondary measures, including a decrease of almost 8 L of blood drawn and a savings of $258 000. No extreme laboratory values were deemed attributable to the interventions. Improvement was sustained for an additional 7 months.
CONCLUSIONS
Targeted interventions, including guideline development, dashboard creation and distribution, electronic medical record optimization, and expansion of noninvasive and point-of-care testing resulted in a significant and sustained reduction in laboratory testing without notable adverse effects.

Identifiants

pubmed: 34088759
pii: peds.2020-000570
doi: 10.1542/peds.2020-000570
pii:
doi:

Substances chimiques

Blood Glucose 0
Carbon Dioxide 142M471B3J
Bilirubin RFM9X3LJ49

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2021 by the American Academy of Pediatrics.

Déclaration de conflit d'intérêts

POTENTIAL CONFLICT OF INTEREST: The authors have indicated they have no potential conflicts of interest to disclose.

Auteurs

Christopher J Klunk (CJ)

Yale School of Medicine, Yale University, New Haven, Connecticut; christopher_klunk@mednax.com.

Renee E Barrett (RE)

Yale School of Medicine, Yale University, New Haven, Connecticut.

Steven M Peterec (SM)

Yale School of Medicine, Yale University, New Haven, Connecticut.

Eleanor Blythe (E)

Yale New Haven Children's Hospital, New Haven, Connecticut; and.

Renee Brockett (R)

Yale New Haven Children's Hospital, New Haven, Connecticut; and.

Marta Kenney (M)

Yale New Haven Children's Hospital, New Haven, Connecticut; and.

Amber Natusch (A)

Yale New Haven Children's Hospital, New Haven, Connecticut; and.

Caitlin Thursland (C)

Yale New Haven Children's Hospital, New Haven, Connecticut; and.

Patrick G Gallagher (PG)

Yale School of Medicine, Yale University, New Haven, Connecticut.

Richard Pando (R)

Yale New Haven Hospital Information Technology Services, New Haven, Connecticut.

Matthew J Bizzarro (MJ)

Yale School of Medicine, Yale University, New Haven, Connecticut.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH